peptidylprolyl isomerase A pseudogene 62Genealiases: []
Q-omics provides the consensus-scored PPIAP62 profile across patient tissues and cancer cell-line models. PPIAP62 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PPIAP62 is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, PPIAP62 RNA expression shows 5,344 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUAD as cancer lineages where PPIAP62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP62 survival associations across molecular data types. PPIAP62 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP62 RNA expression–survival associations across cancer types. High PPIAP62 expression shows unfavorable associations in STAD, OV, BLCA and KICH, but favorable associations in ESCA and SKCM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for PPIAP62 RNA expression.
This table summarizes PPIAP62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP62 shows higher tumor expression in LUAD and COAD. The LUAD box plot shows higher PPIAP62 RNA expression in tumor versus normal tissue (log2 FC = +0.078, t-test p = .010).
This table shows molecular features associated with PPIAP62 in patient tissues and cancer cell lines. In patient samples, PPIAP62 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
